Low-dose sorafenib may improve therapy for head and neck cancer
Monday, May 16, 2011 - 10:30
in Health & Medicine
Adding low doses of the targeted agent sorafenib to the chemotherapy and radiation now often used to treat head and neck cancer might significantly improve patient care and quality of life, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).